This may give up a clue:
Critically Important Finding, Patents Filed – Potential Synergy with New Generation of Diabetes Drugs (SLIDE 3)
– Primary Endpoint in Patients Receiving SGLT2i
• All SGLT2i’s: 60% Hazard Reduction (95% CI; 0.16-1.00) p=0.05 (non-QC’d)
• Empagliflozin: 66% Hazard Reduction (95% CI; 0.12-1.01) p=0.05 (non-QC’d)
Empagliflozin, sold under the brand name Jardiance among others.
Koo
